Brainomix clinches major awards for pioneering AI stroke care technology

Brainomix, a leader in AI imaging technology, has received two prestigious awards, cementing its position as a trailblazer in the healthtech sector. The company was named “Healthtech Company of the Year” by HSBC Innovation Banking at the LSX European Lifestars Awards and “Most Transformative Healthtech Company of the Year” by OBN. These accolades recognise Brainomix’s groundbreaking contributions in AI stroke care, particularly through its AI imaging technology that is transforming the way stroke patients are diagnosed and treated.

AI stroke care revolutionises stroke treatment with Brainomix 360 Stroke

At the heart of Brainomix’s success is its flagship product, Brainomix 360 Stroke, an advanced AI imaging technology that has already shown significant clinical impact across hospitals worldwide. This AI-powered stroke imaging platform has demonstrated remarkable results, enabling clinicians to make faster and more accurate treatment decisions. The platform’s widespread use has been facilitated by recent FDA approvals and endorsements from the UK’s National Institute for Health and Care Excellence (NICE), with Brainomix continuing to expand into markets like the US.

Dr. Michalis Papadakis, CEO and co-founder of Brainomix, shared that the company’s recognition reflects the transformative impact its AI imaging technology is having on global stroke care. He emphasised that Brainomix remains committed to accelerating the adoption of AI stroke care solutions that drive faster diagnoses and improve access to life-saving treatments for patients.

Brainomix 360 Stroke: a breakthrough in AI imaging technology for stroke care

One of the key reasons for Brainomix’s rapid rise in the healthtech sector is the success of Brainomix 360 Stroke, which has been shown to increase mechanical thrombectomy rates by 50%. This critical stroke treatment helps prevent long-term disability in patients with severe strokes due to large vessel blockages. The AI-powered platform makes it possible for clinicians to make quicker, data-driven decisions, improving patient outcomes dramatically.

Dr. Papadakis highlighted that the company’s focus on AI imaging technology aims to redefine stroke care by enabling clinicians to make faster, more precise treatment decisions, which is especially crucial in emergency settings.

AI stroke care expands globally with Brainomix 360 Stroke’s adoption in Hungary and Wales

Brainomix’s AI imaging technology has already been adopted at a national level in countries like Hungary and Wales, where it is improving stroke care efficiency and increasing treatment rates. In Hungary, Brainomix 360 Stroke has led to a more than 50% increase in mechanical thrombectomy rates, with Professor István Szikora from the National Institute of Mental Health, Neurology and Neurosurgery in Budapest praising the platform’s impact on stroke care efficacy.

Similarly, in Wales, the adoption of Brainomix 360 Stroke has been a game-changer, with thrombectomy rates rising by 44%. Dr. Shakeel Ahmad, National Clinical Lead for Stroke in Wales, noted that AI stroke care solutions like Brainomix 360 Stroke help clinicians make faster, more informed decisions, ultimately improving care quality and patient outcomes across the country.

Looking ahead: AI stroke care poised for global impact with Brainomix 360 Stroke

With the growing recognition of its AI imaging technology, Brainomix is poised for continued global expansion. The company’s Brainomix 360 Stroke platform is driving forward the adoption of AI stroke care across healthcare systems worldwide. As more hospitals and health systems implement this technology, Brainomix aims to make life-saving treatments more accessible and efficient for patients, ultimately improving stroke care worldwide. The success of Brainomix underscores the transformative potential of AI imaging technology in reshaping the future of healthcare.